HIGHLIGHTS
- who: Duncan Richards from the The open-label, single-dose-escalation, non-randomized phase , trial [16, ] enrolled and treated a total of , patients, aged, years (inclusion criterion, years), with comprehensively characterized and biopsy-proven systemic amyloidosis (AL, AA, ATTR, AFib and ApoAI)This was a two-part study have published the research work: An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study, in the Journal: (JOURNAL) of 28/01/2013
- what: In this report the authors focus on characterization of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.